Ionis Pharma

We've changed our Twitter account. Please follow us now at @ionispharma. Our new ticker symbol has also changed to $IONS.

[Ionis Pharma @isispharm]

We've changed our Twitter account. Please follow us now at @ionispharma. Our new ticker symbol has also changed to $IONS.

[Ionis Pharma @isispharm]

Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals: Company's Shares Will Trade Under New Ticker Symbo... https://t.co/sl7PnnBORV

[Ionis Pharma @isispharm]

Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patient... https://t.co/97eJToxEWr

[Ionis Pharma @isispharm]

Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS: CA... https://t.co/YCPEO9hF0U

[Ionis Pharma @isispharm]

Isis Pharmaceuticals Earns $2.8M for Advancing ISIS-DMPK-2.5 Rx in Patients with Myotonic Dystrophy Type I: CA... https://t.co/QO6psAgSTQ

[Ionis Pharma @isispharm]

Isis Reports Financial Results and Highlights for Third Quarter 2015: - 2015 Pro Forma Net Income of $25 Milli... https://t.co/hkKI2hTWHe

[Ionis Pharma @isispharm]

Isis Pharmaceuticals Reports Positive Clinical Data From Lp(a) Lowering Drugs: Webcast to review data schedule... https://t.co/fWzbVYXAYO

[Ionis Pharma @isispharm]

Isis Pharmaceuticals to Present at Upcoming Investor Conferences: CARLSBAD, Calif., Nov. 6, 2015 /PRNewswire/ ... https://t.co/ji9cfhzqvG

[Ionis Pharma @isispharm]

Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with F... https://t.co/5KuyZwgnWZ

[Ionis Pharma @isispharm]

Isis Pharmaceuticals to Host Webcast to Review ISIS-APO(a) Rx and ISIS-APO(a)-L Rx Data Presented at American ... https://t.co/lnKnDXereL

[Ionis Pharma @isispharm]

Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies,... https://t.co/4MqZbto78L

[Ionis Pharma @isispharm]

Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodi... https://t.co/rZgdA6j2X1

[Ionis Pharma @isispharm]

Isis Pharmaceuticals to Host Webcast to Review ISIS-TTR Rx Data Presented at 1st European Congress of Heredita... https://t.co/GnVbeEVH9X

[Ionis Pharma @isispharm]

ISIS Pharmaceuticals Earns $5 Million from GSK for Initiation of Phase 1 Study of ISIS-GSK4-L Rx: CARLSBAD, Ca... https://t.co/amtOIwXWvp

[Ionis Pharma @isispharm]

Webcast Alert: Isis Pharmaceuticals' Third Quarter 2015 Financial Results Conference Call: - Webcast scheduled... https://t.co/opmoLHtlQD

[Ionis Pharma @isispharm]

Isis Pharmaceuticals Initiates SHINE Study to Provide ISIS-SMN Rx for Patients With SMA Who Have Completed the... http://t.co/Bf9tfiFOqM

[Ionis Pharma @isispharm]

ISIS-DMPK-2.5Rx for DM1 ongoing phase I/II trial update at 2015 MDF conference. http://t.co/R3PbOXAxCj @CareAndACureMDF @DM1research

[Ionis Pharma @isispharm]

Surfing Dog Helps Kids with SMA Ride The Waves! #SMAshSMA https://t.co/L3vb9OqZxg

[Ionis Pharma @isispharm]

Isis Pharmaceuticals' Collaboration to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and ... http://t.co/NY4PXViIhn

[Ionis Pharma @isispharm]

Isis Pharmaceuticals to Present at Upcoming Investor Conferences: CARLSBAD, Calif., Sept. 3, 2015 /PRNewswire/... http://t.co/VoiB4OTP6z